Gallardo FMA, Ruiz GP, Vera MC

Language: Spanish
References: 21
Page: 90-94
PDF size: 188.10 Kb.

ABSTRACT

Objectives: To establish the effectiveness of low-dose intratympanic gentamicin treatment (a total dose being 4-8 mg) for the control of vertigo caused by Meniere’s disease resistant to medical treatment, as well as to determine the treatment’s impact on hearing abilities.
Patients and methods: This is a longitudinal prospective study. Seventeen patients unresponsive to medical therapy (11 female and 6 male) were treated with 4-8 mg of gentamicin (4 mg per dose). Deafferentiation signs were checked including spontaneous and head-shaking nystagmus, and audiometric control of frequencies of 0.5, 1, 2 and 3 kHz. A follow-up lasting one and a half years was carried out. The criteria established by the 1995 AAO-HNS Committee of Hearing and Equilibrium were used.
Results: Complete control of vertigo (AAO-HNS Class A) was obtained in 14 patients (82%), a significant control was achieved in 2 patients (AAOHNS Class B), and vertigo was not controlled in just one (AAO-HNS Class C). Hearing loss worse than 10 dB occurred in 12%, and an improvement of more than 10 dB in 12%, whereas in 76% of the cases hearing remained unchanged. The intensity and duration of tinnitus decreased in 36% of the patients, whereas it remained the same in the remaining 64%.
Conclusions: The low-dose intratympanic gentamicin treatment is a safe, efficient, low-cost, low-risk method presenting a reduced risk of hypoacusis and thus it should be regarded as the primary treatment for vertigo control when caused by Meniere’s disease resistant to medical treatment.

REFERENCES

1. Pappas DG. Vestibular nerve section: long-term followup. Laryngoscope 1997;107:3-9.

2. Blakley BW. Clinical forum: a review of intratympanic therapy. Am J Otol 1997;18:520-526.

3. Barnerjee AS, Johnson IJ. Intratympanic gentamicin for Meniere’s disease: effect on quality of life as assessed by Glasgow benefit inventory. J Laryngol Otol 2006;120(10):827-831.

4. Schuknecht HF. Ablation therapy in the management of Meniere’s disease. Acta Otolaryngol (Stockh) 1957;132:3-42.

5. Martin E, Perez N. Hearing loss after intratympanic gentamicin therapy for unilateral Meniere’s disease. Otol Neurotol 2003;24:800-806.

6. Pyyko I, Ishizaki H, Kaasines S. Intratympanic gentamicin in bilateral Meniere’s disease. Otolaryngol Head Neck Surg 1994;110:162-167.

7. Atlas JT, Parnes LS. Intratympanic gentamicin for intractable Meniere’s disease. Am J Otol 1999;20:357-363.

8. Committee on Hearing and Equilibrium. Committee on Hearing and Equilibrium guidelines for the diagnosis and evaluation of therapy in Meniere’s disease. Otolaryngol Head Neck Surg 1995;113:181-185.

9. Harner SG, Driscoll CLW, Facer GW, Beatty CW, Mc Donald TJ. Long-term follow up of transtympanic gentamicin for Meniere’s syndrome. Otol Neurotol 2001;22:210-214.

10. Toth AA, Parnes LS. Intratympanic gentamicin therapy for Meneire’s disease: preliminary comparison of two regimens. J Otolaryngol 1995;24:340-344.

11. Hirsch BE, Kameser DB. Intratympanic gentamicin therapy for Meniere’s disease. Am J Otol 1997;18:44-53.

12. Begg EJ, Barclay ML, Duffull SB. A suggested approach to once-daily aminoglycosid dosing. Br J Clinic Pharm 1995;39:605-609.

13. Minor LB. Intratympanic gentamicin for control of vertigo in Meniere’s disease: vestibular signs that specify completion of therapy. Am J Otol 1999;20:209-219.

14. Martín Sanz E, Pérez Fernández N. Gentamicina intratimpánica para la enfermedad de Ménière: análisis de la técnica. Acta Otorrinolaringol Esp 2004;55:270-276.

15. Wu IC, Minor LB. Long-term hearing outcome in patients receiving intratympanic gentamicin for Meniere’s disease. Laryngoscope 2003; 113(5):815-820.

16. Hillman TA, Chen DA, Arriaga MA. Vestibular nerve section versus intratympanic gentamicin for Meniere’s disease. Laryngoscope 2004;114(2):216-222.

17. Abou-Halawa AS, Poe DS. Efficacy of increased gentamicin concentration for intratympanic injection therapy in Meniere’s disease. Otol Neurotol 2002;23:494-503.

18. Beck C, Schmidt CL. 10 years of experience with intratympanically applied streptomycin (gentamicin) in therapy of morbies Meniere’s. Arch Otorhinolaryngol 1978;221:149-152.

19. Johnson LG, Hawkins JE, Kingsley TC, Black FO, Matz GJ. Amynoglycoside-induced cochlear pathology in man. Acta Otolaryngol 1981;383:3-19.

20. Pender D. Gentamicin tympanoclysis: effects on the vestibular secretory cells. Am J Otolaryngol 1982;6:358-367.

21. Harner SG, Kasperbauer J, Facer G, Beatly C. Transtympanic gentamicin for Meniere’s syndrome. Laryngoscope 1998;108(10):1446-1449.